Status:
COMPLETED
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
Lead Sponsor:
Pfizer
Conditions:
Gastrointestinal Stromal Tumors
Eligibility:
All Genders
18+ years
Brief Summary
To monitor use in real practice including adverse events and efficacy on Sutent capsules (Sunitinib malate)
Detailed Description
All the patients prescribed according to approved indications at contracted institutions
Eligibility Criteria
Inclusion
- Patients diagnosed as gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate, or advanced renal cell carcinoma (aRCC) will be included in the study, or patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma.
Exclusion
- Any patient who does not agree that Pfizer and companies working with Pfizer use his/her information will be excluded.
- Patients with hypersensitivity to sunitinib malate or to any other component of Sutent
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
520 Patients enrolled
Trial Details
Trial ID
NCT00444795
Start Date
May 1 2007
End Date
March 1 2015
Last Update
February 1 2017
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Keimyung University Dongsan Medical Center
Jung-gu, Daegu, South Korea, 100-712
2
Daegu Catholic University Medical Center
Nam-gu, Daegu, South Korea, 705-718
3
GangNeung Asan Hospital
Gangneung-si, Gangwon-do, South Korea, 210-711
4
Soonchunhyang University Bucheon Hospital
Bucheon-si, Gyeonggi-do, South Korea, 420-767